August 21st 2023
David F. McDermott, MD, discusses the ongoing, randomized, phase 1/2 LITESPARK-024 trial in patients with advanced renal cell carcinoma, highlighting the eligibility criteria for this clinical trial.
July 14th 2023
David F. McDermott, MD, discusses the randomized phase 2 LITESPARK-024 trial (NCT05468697).
March 5th 2020
David F. McDermott, MD, discusses the research behind combining VEGF inhibitors with PD-1/PD-L1 inhibitors in renal cell carcinoma treatment.
February 12th 2020
David F. McDermott, MD, discusses the toxicities associated with immunotherapy combinations in renal cell carcinoma.
January 8th 2020
David F. McDermott, MD, discusses the use of PD-1 inhibitors in combination with VEGF inhibitors and CTLA-4 inhibitors in metastatic renal cell carcinoma.
November 12th 2019
David F. McDermott, MD, discusses the combination of VEGF TKIs and PD-1 inhibitors in advanced renal cell carcinoma.
June 6th 2019
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the promise of single-agent pembrolizumab in advanced non–clear cell renal cell carcinoma.
March 14th 2019
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses single-agent versus combination immunotherapy in the treatment of patients with renal cell carcinoma.
February 19th 2019
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses single-agent pembrolizumab in the treatment of patients with advanced renal cell carcinoma.
November 14th 2018
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses an analysis of the CheckMate-214 study in advanced renal cell carcinoma (RCC).
January 20th 2018
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses novel immunotherapy combinations for patients with metastatic renal cell carcinoma (RCC).
December 28th 2017
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses immunotherapy as a standard of care for patients with renal cell carcinoma (RCC).
December 14th 2017
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses nivolumab (Opdivo) as a single-agent for the treatment of patients with renal cell carcinoma.
November 30th 2017
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in renal cell carcinoma (RCC).
May 11th 2017
David F. McDermott, MD, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the role of VEGF-targeted therapy in renal cell carcinoma.
April 24th 2017
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the immune-related toxicities for patients receiving checkpoint inhibitors for treatment of their renal cell carcinoma.
March 13th 2017
David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the future of immunotherapies in the treatment of patients with kidney cancer.
March 8th 2017
David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses lessons learned from the recent IMmotion150 trial in renal cell carcinoma (RCC). The open-label, randomized study examined the PD-L1 inhibitor atezolizumab (Tecentriq) alone or in combination with bevacizumab (Avastin) versus sunitinib (Sutent) in patients with untreated advanced RCC.
February 22nd 2017
David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the recent IMmotion150 trial in Renal Cell Carcinoma (RCC).
January 14th 2017
David F. McDermott, MD, Director of Biologic Therapy and Cutaneous Oncology Programs, Hematology and Oncology at the Beth Israel Deaconess Medical Center, discusses the combination of VEGF plus PD-1 in renal cell carcinoma (RCC).